Results 171 to 180 of about 1,232,124 (326)

ATLAS LAr Calorimeter Commissioning for LHC Run-3 [PDF]

M. M. Lyukova, on the behalf of ATLAS Liquid Argon Calorimeter group   +1 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Assessment of genetically modified soybean MON 87769 for renewal authorisation under Regulation (EC) No 1829/2003 (dossier GMFF-2023-21253). [PDF]

EFSA J
EFSA Panel on Genetically Modified Organisms (GMO), Casacuberta J, Barro F, Braeuning A, de Maagd R, Epstein MM, Frenzel T, Gallois JL, Koning F, Messéan A, Moreno FJ, Nogué F, Savoini G, Schulman AH, Tebbe C, Veromann E, Gómez JÁ, Goumperis T, Lenzi P, Camargo AM, Piffanelli P, Raffaello T, Gonzales ABG, Sánchez-Brunete E.   +23 more
europepmc   +1 more source

Requests for Commission reports [8], 1991-07-10/1991-07-24

, 2021
Unknown
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

The EASL–Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality

Tom H. Karlsen, Harry Rutter, Patrizia Carrieri, Shira Zelber‐Sagi, Eivind Engebretsen, Sharon Hutchinson, Kristin Voigt, Indra Neil Guha, Annalisa Berzigotti, Georg Schomerus, Pere Ginès, Marı́a Buti, Patrizia Burra, Michael P. Manns, Aleksander Krag, Sabine Kleinert   +15 more
openalex   +2 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Correction: Opposing needling in the treatment of knee osteoarthritis: an improved study protocol for a randomized controlled trial. [PDF]

Front Med (Lausanne)
Li H, Qian S, Liu Y, Guo Y, Chen X, Hu Y, Fu Q, Li Q, Xiang Y, Liu Y, Wu X, Luo T.   +11 more
europepmc   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

European Commission

International Journal of Integrated Care, 2001
openaire   +6 more sources